TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial
Status:
Withdrawn
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
Studying the effects of Etanercept (an anti-Tumor Necrosis Factor alpha) on early Chronic
Regional Pain Syndrome (CRPS). Our hypothesis is that Etanercept will improve patient
symptoms if given in early CRPS.